Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.16 USD
Change Today -0.12 / -5.26%
Volume 223.2K
OGXI On Other Exchanges
Symbol
Exchange
Munich
NASDAQ CM
As of 8:10 PM 05/28/15 All times are local (Market data is delayed by at least 15 minutes).

oncogenex pharmaceutical inc (OGXI) Key Developments

OncoGenex Pharmaceuticals, Inc. Files Certificate of Amendment to its Amended and Restated Certificate of Incorporation

Following approval by its stockholders at the 2015 annual meeting on May 21, 2015, OncoGenex Pharmaceuticals, Inc. filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation. The Certificate Amendment, which is effective as of May 21, 2015, increased the number of the company's authorized shares of common stock from 50,000,000 shares to 75,000,000 shares.

OncoGenex Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2015

OncoGenex Pharmaceuticals, Inc. reported earnings results for the first quarter ended March 31, 2015. Revenue was $1.4 million compared with $11.7 million for the first quarter of 2014. Revenue earned in the first quarter of 2015 consists of reimbursable clinical trial, manufacturing and preclinical costs incurred by OncoGenex under the collaboration agreement with Teva. Net loss was $4.5 million, or $0.20 per diluted common share, compared with $8.6 million, or $0.59 per diluted common share for the first quarter ended March 31, 2014.

OncoGenex Pharmaceuticals, Inc. to Report Q1, 2015 Results on May 14, 2015

OncoGenex Pharmaceuticals, Inc. announced that they will report Q1, 2015 results at 4:30 PM, US Eastern Standard Time on May 14, 2015

OncoGenex Pharmaceuticals, Inc., Q1 2015 Earnings Call, May 14, 2015

OncoGenex Pharmaceuticals, Inc., Q1 2015 Earnings Call, May 14, 2015

OncoGenex Pharmaceuticals, Inc. - Special Call

To discuss amend the statistical design and analysis plan of its pivotal, international Phase 3 ENSPIRIT trial

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OGXI:US $2.16 USD -0.12

OGXI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OGXI.
View Industry Companies
 

Industry Analysis

OGXI

Industry Average

Valuation OGXI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.1x
Price/Book 1.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ONCOGENEX PHARMACEUTICAL INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.